Compare Otis Worldwide Corp (OTIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Recursion Pharmaceuticals Inc — how do they compare? Otis Worldwide Corp trades at $66.12 (market cap $25.03B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Otis Worldwide Corp is far larger — about 10.8× Recursion Pharmaceuticals Inc's market cap, and Otis Worldwide Corp pays a 2.68% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 65 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| OTIS | RXRX | |
|---|---|---|
Market Cap | $25.03B | $2.31B |
Volume | 2,974,901 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $93.62 | $6.79 |
52-Week Low | $64.05 | $2.84 |
Typical Hold Time | 65 Days | 22 Days |
Enterprise Value | $33.06B | $1.83B |
Dividend Yield | 2.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $65.74, down 1.07% on the day and near its 52-week low, reflecting bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B USD with a net income margin of 10.17%, but faces margin pressure and a high debt-to-asset ratio of 75.54%. Recent news highlights CEO succession plans and mixed sentiment amid weak equipment demand in China.
The outlook is cautious with moderate upside to the $87.00 consensus price target, supported by a dominant service segment and institutional accumulation. Key risks include persistent margin compression, China exposure, and elevated leverage, requiring monitoring of service margin recovery for sustained growth.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
